Search

everythinglearnresearchcommunity

for

Search:↓

After a hair transplant, it's advised to stop using RU58841 and minoxidil to avoid irritation, resuming them 25-30 days post-surgery if the scalp is healed. The user is currently using finasteride, minoxidil, and RU58841, but there are concerns about the safety and efficacy of RU58841 in humans.

User discovered hair fibers, tried Toppik but concerned about ingredients. Considering Boldify (cotton-based, cheaper) and Surethik (keratin-based) as better options.

A user in their early 20s is concerned about minor hair thinning and is considering a hair loss regimen involving PRP sessions, mesotherapy with dutasteride injections, and low-dose finasteride. They dislike minoxidil due to its greasiness and prefer a routine that is easy to maintain.

Availability of topical anti-androgens, especially RU58841, in Australia. Issues with customs seizures and lack of credible local sources.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

User asks if spironolactone can stack with finasteride and pyrilutamide for hair loss treatment. They question why spironolactone is associated with feminizing effects, while RU/pyri/fluridil, which work similarly, are not.

A 23-year-old male plans to temporarily stop finasteride to donate plasma for financial reasons and seeks alternative hair loss treatments like minoxidil, ketoconazole, or RU58841 during this period. He is open to suggestions to prevent further hair loss until he can resume finasteride.

The conversation discusses using oral spironolactone for hair loss in males when 5ari blockers fail. Concerns are raised about spironolactone's side effects, and alternatives like pyrilutamide and breezula are suggested.

The conversation discusses hair loss treatments, specifically oral Minoxidil, also known as Loniten or Alotendin in Bulgaria. It also mentions considering IndiaMart for purchasing options.

Combining minoxidil, pyrilutamide, and copper peptide is questioned, with advice to apply them separately to avoid reactions. Finasteride and minoxidil are recommended for effectiveness.

User experienced side effects from topical finasteride, including penile pain and reduced sexual satisfaction, and is unsure whether to resume or avoid the treatment. They are seeking advice on whether tapering off the drug might help.

Clascoterone 5% solution showed a 539% improvement in hair count compared to placebo, but the actual increase in hair growth is minimal. Users express skepticism about the effectiveness of hair loss treatments.

User asks about Pyrilutamide release in Europe, specifically Germany, and considers importing it from China. No specific treatments mentioned.

Tretinoin may enhance minoxidil's effectiveness for those not responding to minoxidil alone, but it could reduce efficacy for some who are already responding to minoxidil. Tretinoin requires careful use, including skin moisturizing and sun protection due to increased sensitivity.

The user uses Toppik hair fibers to thicken their hairline and has switched from finasteride to dutasteride and oral minoxidil, noticing more hair thickening. Most responses indicate the hair fibers are not noticeable, and many suggest the user doesn't need them as their hair looks natural and good for their age.

The user is seeking a substitute for Tretinoin to enhance the effectiveness of Minoxidil for hair loss. They are considering using Retinol as an alternative.

The user has been inconsistently using a 0.1% finasteride and 5% minoxidil topical treatment for hair loss over the past nine months, along with 1% Nizoral once a week. They aim to improve consistency in their treatment this year and report no side effects.

Clascoterone 5% solution is not yet commercially available, with only the 1% solution currently sold for acne. Users discuss the potential of Clascoterone as a hair loss treatment, comparing it to other anti-androgens like RU58841 and Eucapil.

The conversation is about using alfatradiol as a hair loss treatment. The user is considering adding it to their regimen because it is safe, mild, and easily available in Europe.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

A user is seeking a Minoxidil Response Test kit in the EU without bundled consultations. They mention alternatives like oral minoxidil and tretinoin but prefer the test alone.

Natural vitamins like pumpkin seed oil, saw palmetto, and ecklonia cava are discussed for their potential to lower DHT levels. They may work similarly to finasteride but are significantly weaker.

The user is using RU58841, finasteride, dutasteride, and minoxidil to slow down aggressive hair loss but is still experiencing hair shedding due to high testosterone levels. They plan to use ostarine to lower testosterone and prevent hair loss while maintaining muscle mass, and will continue using the other treatments.

Clascoterone and RU58841 are compared for effectiveness in treating hair loss. The discussion involves treatments like Minoxidil, finasteride, and RU58841.

Koshine 826 (Pyrilutamide) has mixed reviews, with some users experiencing side effects like insomnia and others seeing minimal results. Concerns about the company's transparency and lack of progress photos are noted.

The conversation is about the order of applying hair loss treatments, specifically The Ordinary serum and Zix. The user is unsure which to apply first due to the alcohol content in Zix.

Botox injections increase hair density in patients with androgenetic alopecia. Combining Botox with finasteride yields even better results.

The conversation discusses alternatives to 5AR inhibitors for hair loss treatment, suggesting options like minoxidil, KX-826, pyrilutimide, microneedling, and topical bicalutamide. Concerns about side effects and the effectiveness of these treatments are also highlighted.

A new topical finasteride has been approved in France, providing an alternative to oral finasteride with potentially fewer side effects. Users discuss the pros and cons of topical versus oral treatments, with some opting to create their own solutions to save money.

Combining finasteride with minoxidil and tretinoin is discussed, with concerns about potential overdose. It is suggested that high doses of finasteride do not provide additional benefits beyond 1 mg.